Clinical and Translational Science, Volume 19, Issue 5, May 2026.ABSTRACT Clopidogrel is an antiplatelet agent widely utilized in cardiology. It is a prodrug activated in the liver by the cytochrome P450 isoform CYP2C19. Variability in the CYPC2C19 gene influences the activation and efficacy of clopidogrel. This is covered in guidelines from the Clinical Pharmacogenetics Implementation Consortium, the Dutch ...
Cinzia Dello Russo +5 more
wiley +1 more source
Achieving door-to-balloon time ≤ 90 minutes in ST-elevation myocardial infarction: a retrospective clinical audit from a tertiary care centre in India. [PDF]
Int J Emerg MedKrishnan R +5 more
europepmc +1 more source
Prehospital Risk Stratification Using Unsupervised Machine Learning in STEMI
European Journal of Clinical Investigation, Volume 56, Issue 5, May 2026.Machine learning identified three phenotypes with 30‐day mortality of 3.4%, 22.1%, and 75%. Phenotype‐2 reveals an "occult high‐risk" group: hemodynamically stable yet six‐fold higher mortality. ABSTRACT Background ST‐elevation myocardial infarction (STEMI) exhibits substantial clinical heterogeneity complicating prehospital risk stratification ...
Ana Ramos‐Rodríguez +7 more
wiley +1 more source
Impact of type 2 diabetes mellitus on in-hospital outcomes in patients with ST-elevation myocardial infarction: A nationwide study in Germany. [PDF]
Metabol OpenSchmitt VH +9 more
europepmc +1 more source
European Journal of Clinical Investigation, Volume 56, Issue 5, May 2026.This meta‐analysis evaluated clinical outcomes following coronary bioadaptor implantation compared with drug‐eluting stents. Pairwise analysis of randomised trials showed no significant difference in target‐lesion failure at 1 year. Complementary single‐arm landmark analyses demonstrated low late event rates between 6 and 12 months and 6 and 24 months.
Simon Wölbert +7 more
wiley +1 more source
Pathways of Care for Patients Who Undergo Primary Percutaneous Coronary Intervention for STEMI: A Review of "<i>Ideal</i>" vs. "<i>Real-world</i>" Clinical Scenarios. [PDF]
Rev Cardiovasc MedKwok CS +4 more
europepmc +1 more source
B Cell Subsets and Atherosclerosis: Updates and Emerging Concepts
Immunological Reviews, Volume 339, Issue 1, May 2026.ABSTRACT Atherosclerotic cardiovascular disease (ASCVD) is increasingly recognized not just as a lipid‐driven disease, but as a complex interplay between vascular cells and the immune system. Accumulating evidence highlights a central, yet heterogeneous role for B cells in atherogenesis, with distinct subsets displaying opposing roles.
Sophieke Lems +3 more
wiley +1 more source
Predictors of Adverse 30-Day Outcomes After Right Coronary Artery ST-Elevation Myocardial Infarction. [PDF]
J Clin MedBate AP +7 more
europepmc +1 more source
Sex Differences in Outcomes After STEMI: Effect Modification by Treatment Strategy and Age
JAMA Internal Medicine, 2018 E. Cenko +12 more
semanticscholar +1 more source
T Cell Receptor Repertoires Across the Continuum of Vascular, Myocardial, and Age‐Related Diseases
Immunological Reviews, Volume 339, Issue 1, May 2026.ABSTRACT Cardiovascular diseases (CVD) are shaped by a complex interplay with immune mechanisms. In particular, the distinct roles of antigen‐specific T cell mechanisms are emerging as critical determinants across a broad spectrum of conditions, ranging from atherosclerosis, myocardial infarction (MI), heart failure (HF), and myocarditis. Because these
Leon Richter +3 more
wiley +1 more source